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Paying Women For Their Eggs For
Use In Stem Cell Research
Pamela Foohey
On June 11, 2009, the Empire State Stem Cell Board
(“Board”), which administers the $600 million in New York
State funds allotted to stem cell research, voted to allocate a
portion of those funds to compensate women up to $10,000 for
“donating” their eggs for use in stem cell research.1 The
Board‟s decision makes New York the first state to
affirmatively allow state funds to be used to compensate
women for providing their eggs for use in stem cell research
beyond mere reimbursement of associated medical and other
expenses,2 and, similarly, distinguishes it from most

Post-Graduate Research Fellow, Harvard Law School; Associate,
Dorsey & Whitney LLP. J.D., Harvard Law School, 2008; B.S., New York
University, Stern School of Business, 2004. Special thanks to Professor
Russell Korobkin for helpful input on this Article. The views expressed in
this Article are solely those of the author.
1. Statement of the Empire State Stem Cell Board on the Compensation
of
Oocyte
Donors,
http://stemcell.ny.gov/docs/ESSCB_Statement_on_Compensation_of_Oocyte_
Donors.pdf (last visited Mar. 12, 2010) [hereinafter Statement of Board]; New
York State Stem Cell Science, Frequently Asked Questions about NYSTEM,
http://stemcell.ny.gov/nystem_faq.html (last visited Mar. 12, 2010). Though
“donation” is not an accurate term as applied to women selling their eggs
(also called oocytes) for sums greater than the associated medical and other
expenses, the Board‟s decision and common parlance refer to such selling as a
donation.
2. California permits reimbursement for certain expenses. CAL. HEALTH
& SAFETY CODE § 125355 (West 2009). Massachusetts, Connecticut, Indiana,
and Maryland specifically forbid compensation. 105 MASS. CODE REGS.
960.006(a) (2009); CONN. GEN. STAT. ANN. § 19a-32d(c)(3) (West 2006 Supp.);
IND. CODE ANN. § 35-46-5-3 (West 2009); MD. CODE ANN. ECON. DEV. § 10439(b) (West 2009). Louisiana explicitly prohibits the sale of eggs. LA. REV.
STAT. ANN. § 9:122 (2009). Several states ban the sale of all body parts for
valuable consideration. See Michelle Bercovici, Biotechnology Beyond the
Embryo: Science, Ethics, and Responsible Regulation of Egg Donation to
Protect Women’s Rights, 29 WOMEN‟S RTS L. REP. 193, 204-06 (2008) (listing
states and noting that these statutes can be read to prohibit the sale of eggs);
but see Kenneth Baum, Golden Eggs: Towards the Rational Regulation of
Oocyte Donation, 2001 BYU L. REV. 107, 127 (2001) (arguing that such
statutes should not be read to cover eggs because “oocytes are, for all
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international countries, which either prohibit payment of any
amount to women donating their eggs for research purposes or
limit compensation to reimbursement for certain expenses.3 In
contrast, the decision aligns New York‟s approach with
national policy concerning supplying eggs for reproductive
purposes.4 Indeed, New York permits payment of up to
$10,000 to women providing their eggs for reproductive
purposes, and, in the United States, women of certain
backgrounds and with certain physical characteristics are
offered, at least initially, as much as $50,000 and $100,000 for
their eggs.5
As expected, the Board‟s decision elicited divergent
reactions. Proponents focused on the potential advancements
practical purposes, replenishable”). See also Russell Korobkin, Buying and
Selling Human Tissues for Stem Cell Research, 49 ARIZ. L. REV. 45, 48 (2007)
(listing states with statutes that appear to forbid “tissue sales for research
purposes”).
3. England allows reimbursement for reasonable out-of-pocket expenses
with up to an additional 250 pounds for lost earnings. Likewise, Canada,
Australia, and Singapore prohibit compensation beyond reasonably-incurred
expenses. Bercovici, supra note 2, at 204-06; Debora Spar, Ph.D., The Egg
Trade: Making Sense of the Market for Human Oocytes, 13 NEW ENG. J. MED.
1289, 1291 (2007); Baum, supra note 2, at 129. Sweden, Israel, and South
Korea forbid reimbursement or compensation in any amount. Spar, supra, at
1291; Erika Check, Ethicists and Biologists Ponder the Price of Eggs, 442
NATURE 606, 606 (2006); Baum, supra note 2, at 129. Citing the risks of egg
production and extraction, Japan bans egg donation altogether. Check,
supra, at 606.
4. In the United States, eggs “may be sold at a „fair price‟ for use in
fertility programs.”
Loane Skene, Recent Developments in Stem Cell
Research: Social, Ethical and Legal Issues for the Future 22 (Univ. of
Melbourne, Legal Studies Research Paper No. 385), available at
http://www.lawgenecentre.org/stemcellfuture.pdf; see also Korobkin, supra
note 2, at 49 (noting that, “in most states, gametes are actively bought and
sold for reproductive purposes”). Most international countries disallow
payment of any amount or limit compensation to reimbursement, thereby
aligning their payment policies.
See, e.g., HUMAN FERTILISATION &
EMBRYOLOGY AUTH., SEED REPORT (2005) (Eng.), available at
www.hfea.gov.uk/docs/SEEDReport05.pdf; Lori P. Knowles, Canada’s
Regulatory Oversight of Stem Cell Research, Stem Cell Network (2009),
available
at
http://www.stemcellnetwork.ca/uploads/File/whitepapers/Canada-RegulatoryOversight-of-Stem-Cell-Research.pdf (Can.).
5. Statement of Board, supra note 1 (describing New York‟s policy as to
compensation); DEBORA L. SPAR, THE BABY BUSINESS: HOW MONEY, SCIENCE,
AND POLITICS DRIVE THE COMMERCE OF CONCEPTION 45-46 (2006) (noting that,
as of 2004, amounts paid for eggs generally ranged from $3,000 to $8,000 per
donation cycle).
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in stem cell research and the inconsistency between permitting
payment in the reproductive context and disallowing payment
in the research context.6 Opponents voiced fears that payment
might unduly induce women to donate their eggs.7
Anticipating such opposition, in its written statement, the
Board opined that “reasonable reimbursement coupled with
other safeguards protects against [the possibility that women
may be unduly influenced],” and that “a policy prohibiting
reasonable payments because they may interfere with a
woman‟s ability to weigh the risks and benefits of donation is
unnecessarily paternalistic.”8 The Board further noted that in
addition to “rigorous review by an institutional oversight
committee, prohibition against payment of valuable
consideration, and adherence to [the American Society of
Reproductive Medicine (“ASRM”)]‟s guidelines,”9 it intended to
require “full disclosure of all physical and psychological risks
associated with oocyte donation,” prescribe that “informed
consent be obtained through a dynamic process focused on the
donor‟s comprehension of the information provided,” and
mandate the “availability of psychological counseling prior to
donation.”10
Despite the Board‟s assurances, on October 9, 2009,
Feminists Choosing Life of New York (“FCLNY”),11 a self-

6. See Libby Nelson, New York State Allows Payment for Egg Donations
for Research, N.Y. TIMES, June 26, 2009, at A20; Rob Stein, New York to Pay
for Eggs for Stem Cell Research, WASH. POST, June 26, 2009, at A04.
7. See Nelson, supra note 6; Stein, supra note 6.
8. Statement of Board, supra note 1.
9. Id. In regards to supplying eggs for reproduction or research, ASRM
guidelines provide that paying “sums of $5,000 or more require[s]
justification and sums above $10,000 are not appropriate.” Ethics Comm.,
Am. Soc‟y for Reprod. Med., Financial Compensation of Oocyte Donors, 88
FERTILITY
&
STERILITY
305,
308
(2007),
available
at
http://www.asrm.org/Media/Ethics/financial_incentives.pdf. As to safeguards,
ASRM guidelines state that “[c]ompensation should not vary according to the
planned use of the oocytes . . . , the number or quality of oocytes retrieved . . .
, the outcome of prior donation cycles, or the donor‟s ethnic or other personal
characteristics”; that entities compensating women for supplying their eggs
“should adopt effective information disclosure and counseling processes”; and
that entities “should ensure equitable and fair provision of [physician]
services to donors.” Id. at 308, 305.
10. Statement of Board, supra note 1.
11. Feminists
Choosing
Life
of
New
York,
About
Us,
http://www.feministschoosinglife.org/ (last visited Mar. 12, 2010).
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described “pro-life feminist” organization, filed suit in New
York State court to block the use of state funds to pay women
who supply their eggs for stem cell research.12 FCLNY argues
that the compensation program “provides significant monetary
inducements to women to engage in [a] painful and risky
procedure, which in part disproportionately appeals to
economically vulnerable women,” while “fail[ing] to
satisfactorily provide for informed consent and other
safeguards to ensure adequate disclosure to women of the risks
of egg harvesting.”13 In advancing this argument, FCLNY
identifies an important difference between compensating
women who provide their eggs for reproductive purposes and
compensating women who supply their eggs for research
purposes: for reproductive purposes, younger women with
particular backgrounds are almost exclusively sought after,
while for research purposes, researchers can use eggs from a
diverse set of women.14 This appeal to even younger and older,
less educated, and poorer women makes compensating women
for providing eggs to be used in stem cell research precarious:
women targeted to provide their eggs for research purposes
may be more likely to agree to do so without clear thought or
any real choice.
This Article analyzes the Board‟s decision, first outlining
the aims of stem cell research, the logistics of egg production,
and why payment is necessary to obtain a sufficient number of
eggs for stem cell research purposes; then summarizing the
arguments regarding compensation; and finally, relying on
insights from those arguments, focusing on the safeguards the
12. Verified Petition for the Petitioner, Feminists Choosing Life of New
York v. Empire State Stem Cell Board, No. 8594/2009 (N.Y. Sup. Ct. Oct. 9,
2009),
available
at
http://www.feministschoosinglife.org/files/FCLNY_vs_State_Stem_Cell_Board
_Signed.pdf.
13. Id. at 9. For FCLNY‟s additional arguments, see id. at 7-10.
14. Id. at 9 (“The [compensation program] provides significant monetary
inducements to women . . . who may not meet the „profile‟ required to receive
private payments for their eggs to be used for in vitro fertilization
purposes.”); see also Sarah B. Angel, The Value of the Human Egg: An
Analysis of Risk and Reward in Stem Cell Research, 22 BERKELEY J. GENDER
L. & JUST. 183, 197-98 (2007) (noting that “evidence suggests that . . . women
who have donated for general research purposes are not inclined to
participate as donors for IVF programs . . . ,” that “researchers only require
that the oocytes contain healthy cytoplasm,” and that “research donors‟
genetic makeup is irrelevant”).
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Board set out in its written statement. In evaluating the
decision, this Article concludes that the Board has not crafted
sufficient safeguards to protect against the possibility that
women may be unduly influenced to supply their eggs, as it
sought to do. Thus, the Article ends by identifying further
safeguards that the Board should adopt in order to confront the
full expanse of women‟s potential interactions with its
compensation program, both as to guarding against undue
influence and exploitation, and creating a program that
addresses the continuing needs of the women that New York
entices with large sums of money to provide their eggs.
I.

Stem Cell Research and the Need To Pay For Eggs

Stem cell research has the potential to lead to treatments
and cures for an array of diseases. With stem cells, researchers
can study how cells differentiate, thereby learning the causes of
various diseases, then use the differentiated cells to test
medical drugs and treatments, and, hopefully, eventually use
the stem cells to cure diseases.15 The stem cells required for
such research and future treatments can come from two
sources: human embryonic stem cells (“hESCs”) and human
adult stem cells.16 Though researchers have derived stem cells
adequate for research from human adult stem cells, some
researchers argue that the most useful stem cells originate
from hESCs and, accordingly, that research using hESCs must
continue.17 HESCs, in turn, come from blastocysts harvested
approximately five days following fertilization. The necessary
blastocysts, in turn, are created in three ways: previously as
part of in vitro fertilization (“IVF”) treatment and subsequently
donated to be used for research purposes; specifically for
research purposes by uniting human egg and sperm; and by
removing the nucleus of a human egg and replacing it with the
nucleus of a human body cell, thereby creating a “clonal
15. Russell Korobkin, Autonomy and Informed Consent in
Nontherapeutic Biomedical Research, 54 UCLA L. REV. 605, 608 (2007).
16. Id. at 609.
17. Lisa C. Ikemoto, Eggs as Capital: Human Egg Procurement in the
Fertility Industry and the Stem Cell Research Enterprise, 34 SIGNS: J. WOMEN
CULTURE & SOC‟Y 763, 772-73 (2009); Skene, supra note 4, at 3-4. See also
infra note 19.
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embryo.”18
Of these three methods, the last process holds the most
promise because it yields a blastocyst with genetic material
matching the provider of the body cell and, thus, may be used
to create individually-tailored stem cell therapies.
This
process, however, requires a fresh human egg, an egg
necessarily extracted from a woman.19 Moreover, regardless of
the method used, in the initial stages of research, to create a
single stem cell line, researchers estimate that they will need
over two hundred blastocysts; as technology advances,
researchers most likely still will need over a dozen
blastocysts.20 Unless researchers use blastocysts discarded
following IVF treatments and subsequently donated for use in
stem cell research—of which, given the number of blastocysts
needed to create one stem cell line, it is unlikely enough will be
donated to fulfill the needs of researchers—these blastocysts
will need to be created by using human eggs. The best and
only practical source for human eggs at this time is women.21
Accordingly, in order for stem cell research to proceed,
thousands upon thousands of eggs must be extracted from
women.
Egg production and extraction is a complicated, multi-step
process that brings with it a long list of restrictions and shortterm and potentially long-term health risks. In brief, following
18. Korobkin, supra note 15, at 609; Emily Galpern, Beyond Embryo
Politics: Women’s Health and Dignity in Stem Cell Research, WOMEN‟S
HEALTH
ACTIVIST,
May/June
2006,
available
at
http://www.geneticsandsociety.org/article.php?id=1999.
19. Ikemoto, supra note 17, at 773; see also Elizabeth Gerber, Recent
Development in Health Law: California Limits Egg Donor Compensation in
Privately-Funded Research, 35 J.L. MED. & ETHICS 220, 221 (2007) (noting
that though stem cell lines can be created without using human eggs, “the
use of eggs . . . is the only method thought to have the potential ability to
create „stem cells that are genetically matched to patients,‟ which may then
be used to develop replacement organs”).
20. Ronald M. Green, Five Ethical Questions for SCNT Stem Cell
Research, 9 MINN. J. L. SCI. & TECH. 131, 137 (2008).
21. See Lori Gruen, Oocytes For Sale?, 39 METAPHILOSOPHY 285, 287-90
(2007) (listing the other methods by which eggs may be procured and
discussing why they are not feasible alternatives); Angel, supra note 14, at
195-96 (describing alternatives to donated eggs for stem cell research and
concluding that “because of the dearth of alternative oocyte sources, [stem
cell research] will be unable to achieve its potential if compensation bans” are
implemented).

https://digitalcommons.pace.edu/plr/vol30/iss3/4

6

906

PACE LAW REVIEW

[Vol. 30:3

a battery of ultrasounds and blood tests, a woman providing
her eggs receives a three-week series of drug injections that
shut down her ovaries. After her ovaries shut down, she begins
a regime of ovarian-hyper-stimulating hormones.
These
hormones cause between ten and twenty eggs to mature in her
ovaries. Following sufficient maturation, a doctor sedates the
woman with light anesthesia and extracts the mature eggs by
inserting a needle through the vaginal wall, into the ovary, and
suctioning out the follicular fluid that contains the eggs.22
Throughout this process, the woman must follow-up with a
doctor repeatedly to have her hormone levels checked through
blood tests and the progress of her ovaries monitored by
ultrasound. Also during this process, she may not engage in
unprotected sex, smoke, drink alcohol, or take drugs,
prescription or otherwise, without prior permission.23 In total,
the woman spends approximately fifty-six hours in a “medical
setting.”24
At each step of this process, the woman supplying her eggs
is subject to numerous health risks. The drugs designed to
shut down ovarian function suppress a woman‟s natural
hormone production, which may lead to “hot flashes, difficulty
with short-term memory, and insomnia.”25 These drugs also
may cause vaginal dryness, hypertension, formation of blood
clots, intestinal bleeding, fluid accumulation in the limbs,
swelling of the limbs, numbness of the limbs, fatigue,
depression, mood swings, chest pain, bone pain, joint pain,
muscle pain, migraines, vision problems, dizziness and
blackouts, nausea, vomiting, diarrhea, anemia, and thyroid
enlargement.26 Moreover, the FDA has not approved Lupron,
the drug most often prescribed to shut down ovaries, for such
22. Bercovici, supra note 2, at 194-95.
23. Kimberly D. Krawiec, Altruism and Intermediation in the Market for
Babies, 66 WASH. & LEE L. REV. 203, 220-21 (2009).
24. Angel, supra note 14, at 203.
25. Bercovici, supra note 2, at 195.
26. Gerber, supra note 19, at 221; Galpern, supra note 18, at 2; Human
Cloning and Embryonic Stem Cell Research After Seoul: Examination
Exploitation, Fraud, and Ethical Problems in the Research: Hearing Before
the Subcomm. on Criminal Justice, Drug Policy, and Human Resources of the
H. Comm. on Government Reform, 109th Cong. 79 (2006) (statement of Judy
Norsigian, Executive Director, Our Bodies Ourselves) [hereinafter Norsigian
Statement],
available
at
http://frwebgate.access.gpo.gov/cgibin/getdoc.cgi?dbname=109_househearings &docid=f:29580.pdf.
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use. Although Lupron‟s “off-label” use is allowed, and despite
the fact that since 2006 the FDA has received more than 6,000
complaints regarding the drug, including twenty-five deaths
related to “off-label” use, little research exists about the exact
short and long-term effects of its use in connection with egg
extraction.27
The drugs that hyper-stimulate the ovaries may cause
even more serious side effects. In addition to the relatively
minor short-term side effects of mood swings, water retention,
general abdominal discomfort, and ovarian swelling and cysts,
hyperstimulation
of
ovaries
can
cause
ovarian
hyperstimulation syndrome (“OHSS”), which can result in
dehydration, nausea and vomiting, kidney problems and
failure, liver problems, fluid retention in the lungs, blood clots,
the formation of cysts in the ovaries, and shock.28 In rare
instances, OHSS becomes life-threatening and requires the
removal of the affected ovary or ovaries, and “can lead to stroke
and „arterial occlusion with loss of limb or death.‟”29 Overall,
“physicians report that even moderately severe OHSS can be a
„devastating, frightening experience for a donor.‟”30
Twenty to thirty-three percent of women undergoing the
egg extraction process report the less severe short-term side
effects.31 OHSS affects about six percent of women.32 The
27. Galpern, supra note 18, at 2; Diane Beeson & Abby Lippman, Egg
Harvesting for Stem Cell Research: Medical Risks and Ethical Problems, 13
REPROD. BIOMEDICINE ONLINE 573, 575 (2006).
28. Krawiec, supra note 23, at 221; Bercovici, supra note 2, at 195;
Galpern, supra note 18, at 2; Norsigian Statement, supra note 26.
29. Norsigian Statement, supra note 26, at 81 (referencing memorandum
of Dr. Suzanne Parisian). See also Krawiec, supra note 23, at 221; Galpern,
supra note 18, at 2; John Reichard, Stem Cell Bill Foes Warn of Egg Donation
Risks, CQ HEALTHBEAT NEWS, Apr. 10, 2007, available at
http://public.cq.com/docs/hb/hbnews110-000002487888.html (reporting that,
at a United States Senate briefing, “Jennifer Lahl of the Center for Bioethics
and Culture Network, described 34 cases of arterial thrombosis she said have
resulted from assisted reproductive technologies entailing ovarian
stimulation. Fifteen of the cases involved strokes, three involved heart
attacks, and two cases were fatal”).
30. Angel, supra note 14, at 203.
31. Galpern, supra note 18, at 2.
32. Gerber, supra note 19, at 221.
Some experts contend that
implementation of prevention strategies can reduce the risk of OSHH, such
as identifying women who are especially at risk of developing OSHH. Angel,
supra note 14, at 204-05. “[Y]oung age, ovary abnormalities, low body
weight, a history of allergies, and underlying thrombophia,” as well as
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more serious short-term side effects of the drugs, including
those associated with OHHS, affect between 0.1 and eight
percent of women supplying their eggs.33 For example, 1.4 in
every 1,000 women undergoing ovarian hyperstimulation
experience kidney failure,34 and, as of 2005, five women in the
United Kingdom have died of complications related to OHSS.35
Additionally, the process used to remove the mature eggs
may cause bleeding and infection. During the extraction, the
bowel, bladder, and nearby blood vessels may be punctured,
resulting in internal bleeding that may require major
abdominal surgery.36 Finally, sedation by anesthesia carries
risks of its own.37
The long-term health risks of shutting-down a woman‟s
ovaries and then hyperstimulating them to produce numerous
eggs remain unknown and generally unstudied. Some small,
limited studies posit a link between breast, ovarian, and
uterine cancer and the drugs used to suppress ovarian function
and hyper-stimulate the ovaries.38 Anecdotal stories of women
who have undergone the production and extraction procedure
later developing colon cancer at extremely young ages similarly
identify a potential link between egg donation and colon
cancer.39 Studies also link the drugs with future infertility.40
When faced with all these restrictions and potential side
“irregular menstrual cycles or poly-cystic ovaries” may increase the risk of
developing OSHH. Id.
33. Galpern, supra note 18, at 2.
34. Bercovici, supra note 2, at 195.
35. Beeson & Lippman, supra note 27, at 575.
36. Krawiec, supra note 23, at 221.
37. Angel, supra note 14, at 209 (“Mortality risk associated with
anesthesia are low and amount to less than one per 300,000.”).
38. Id. at 207-09; Gerber, supra note 19, at 221. One study found that
women who were given a certain ovarian hyperstimulation drug “had 11
times the risk of developing ovarian tumours compared with the general
population.” Helen Pearson, Health Effects of Egg Donation May Take
Decades To Emerge, 442 NATURE 607, 607 (2006).
39. See It’s Time for an Egg Donor Registry and Long-term Follow-up,
110th Cong. (2007) (testimony of Jennifer Schneider, M.D.).
40. Angel, supra note 14, at 205-07; Bercovici, supra note 2, at 195;
Gerber, supra note 19, at 221. For a detailed analysis of the known and
potential risks of egg donation, see Institute of Medicine & National Research
Council, Workshop Report, Assessing the Medical Risks of Human Oocyte
Donation
for
Stem
Cell
Research,
available
at
http://www.nap.edu/openbook.php?isbn=030910355X.
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effects, it is understandable why payment may be necessary.
The experiences of the several states that provide funds for
stem cell research demonstrate that compensation is essential
in order for researchers to obtain the eggs necessary for stem
cell research to proceed. Though these states provide funding
for stem cell research, they prohibit compensation beyond mere
reimbursement for associated medical and other expenses to
women supplying their eggs for that research.41 Consequently,
stem cell research largely remains at a standstill because
researchers do not have enough human eggs.42 For example,
though the Harvard Stem Cell Institute spent $100,000 over a
period of a year and a half on advertising to recruit egg donors,
during that time, it did not find a single woman willing to
donate her eggs. The director of the Institute explained: “We‟ve
had hundreds of calls from women who are interested in
donating, but when they find out about the time, effort, and
pain involved, they simply can‟t take the time to go forward.”43
Given that stem cell research using hESCs will continue,
and that it is questionable whether enough blastocysts
discarded following IVF treatments will be donated to stem cell
research for such research to advance without creating
additional blastocysts, this need to pay women for supplying
their eggs for stem cell research to proceed creates a dilemma:
the process of egg extraction is so time-consuming and painful
and comes with so many risks that in order for researchers to
have a sufficient number of eggs, payment seems necessary,
but the process is so time-consuming and painful and comes
with so many risks that the amount of payment necessary to
persuade women to provide their eggs has the potential to
create situations in which women are unduly induced or
exploited44 into supplying their eggs or agreeing to the process
41. See supra note 2 and accompanying text.
42. Emily Singer, Human Therapeutic Cloning at a Standstill: A Lack of
Human Eggs Has Created a Major Roadblock in One of the Most Promising
Areas of Stem-Cell Research, TECH. REV., Oct. 9, 2007, available at
http://www.technologyreview.com/Biotech/19488/.
43. Id.
44. If an inducement is undue, “the inducement . . . impairs, not just
influences, judgment, so that „the offered good leads to poor judgment which
makes [a person] take unnecessary, unreasonable, and excessive risks of
harm,‟” or the inducement is coercive. Gruen, supra note 21, at 295, 297.
Coercion is “an extreme form of influence by another person that completely
controls a person‟s decision.” J.P. Bentley & P.G. Thacker, The Influence of
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without sufficient understanding of the risks involved. It is
this dilemma that opponents and proponents of compensation
primarily have discussed since the emergence of stem cell
research and that the Board confronted when it outlined its
compensation policy.
II. Arguments Regarding Compensation
In order to evaluate the Board‟s safeguards, it is important
to understand the arguments of opponents and proponents of
compensation, which the Board attempted to balance when it
crafted its decision. This section summarizes those arguments;
unless otherwise indicated, this section recounts the opinions of
commentators and not my own.
The main arguments
regarding compensating women who provide their eggs for
stem cell research divide into two categories: (a) arguments
about undue inducement and exploitation, and (b) arguments
about commodification.
A. Undue Inducement and Exploitation
First, analogizing to live organ donation, opponents of
compensation argue that the underlying risks of egg production
and extraction are so serious and unknown that allowing
compensation would create an undue incentive to submit to a
high-risk procedure without a concomitant personal benefit
beyond the payment.45 In the context of most medical research,
donors anticipate receiving a direct medical benefit from their
donation within their lifetime, either for themselves or for a
loved one. Likewise, when women provide their eggs for
reproductive purposes, they may receive a discount on the cost
of their reproductive therapies from which they hope to receive
Risk and Monetary Payment on the Research Participation Decision Making
Process, 30 J. MED. ETHICS 293, 293 (2004). In contrast, and acknowledging
that “[t]he concept of exploitation, its meaning, and its appropriate
application” are debated heavily, as a “minimal understanding,” essentially,
“an individual exploits another individual if one of them has something the
other needs and stands in a powerful relationship over the latter, and uses
that relationship and the fact that he or she has something the subordinate
needs, to take unfair advantage of the less powerful individual.” Gruen,
supra note 21, at 293.
45. Gerber, supra note 19, at 221.
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a direct medical benefit or they may benefit in knowing that a
child may be born from their provision, possibly to someone
they know. In contrast, stem cell research is far from
producing any analogous benefit: at this point, researchers will
use eggs for research only and not for stem cell therapies.46
Considering this lack of direct benefit beyond the payment,
opponents fear that conflicts of interest will cause researchers
to misrepresent the risks of egg extraction or neglect to obtain
informed consent, or that the norms of the doctor-patient
relationship, in which the patient‟s care is the doctor‟s primary
concern, will be violated such that doctors discount or do not
attend to the health of women supplying their eggs.47
Opponents of compensation further argue that only by
prohibiting payment and other “inducements” will women truly
be able to consent to the egg extraction procedure.48 Opponents
cite the experience of women with a research lab in South
Korea. In 2004, Dr. Hwang Woo Suk became the first person to
successfully clone a human embryo and extract a stem cell line
from that cloned embryo. Shortly before the announcement,
reporters discovered that Dr. Hwang had either paid women in
violation of South Korea‟s ban on compensation or recruited
women directly from his lab to donate the eggs he used to
create the stem cell line.49 Opponents contend that Dr. Hwang
compelled these women to give their eggs with money and
promises of continued employment.50 Similarly, in the wake of
the recent financial crisis, fertility clinics in the United States
reported a surge in women inquiring about egg donation for
reproductive purposes. In some instances, women‟s husbands

46. David Magnus & Mildred K. Cho, Issues in Oocyte Donation for Stem
Cell Research, SCIENCE, June 17, 2005.
47. See, e.g., Beeson & Lippman, supra note 27, at 575-77 (discussing
potential conflicts of interest); Judith F. Daar, Regulating the Fiction of
Informed Consent in ART Medicine, 1 AM. J. OF BIOETHICS 19, 19-20
(questioning “whether informed consent can ever be a practical reality in a
field of medicine grounded in the trilogy of rapidly advancing technologies,
emotionally charged expectations, and commercialism”).
48. See Radhika Rao, California’s Stem Cell Initiative: Converting the
Legal and Policy Challenges: Coercion, Commercialization, and
Commodification: The Ethics of Compensation for Egg Donors in Stem Cell
Research, 21 BERKELEY TECH. L.J. 1055, 1058-59 (2006).
49. Id. at 1059-60; see also Korobkin, supra note 2, at 53.
50. Rao, supra note 48, at 1059-60.
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called the clinics themselves, “offering up their wives.”51 These
examples highlight concerns regarding women being pressured
or exploited into supplying their eggs, and lead opponents of
compensation to call for the protection of women who may
agree to provide their eggs when presented with payment when
they otherwise would not, especially considering that a portion
of these women may be less economically advantaged than
women providing their eggs for reproductive purposes and,
thereby, may be enticed to the point of undue inducement by
monetary incentives.52
In response, proponents of compensation assert that the
substantial risks associated with, and the rigors of, egg
extraction constitute the very reasons to permit payment: it is
only fair that women receive compensation.53 Also, if women
do not receive compensation, every individual and entity
involved in stem cell research but the woman providing her
eggs benefits monetarily or in some other way.54 According to
proponents, it is precisely because a woman supplying her eggs
may not see a personal benefit from stem cell research that
payment is necessary.
Additionally, proponents of compensation emphasize that
such non-payment may reinforce the perception that women
should be willing altruistically to undergo a lengthy, painful,
and risky procedure in order to advance the health and wellbeing of others, especially when that contribution is necessarily
intertwined with reproduction. Particularly considering that
the standard practice is to allow compensation to medical
research subjects,55 proponents worry this non-payment
scheme may entrench the notion that two of women‟s primary
functions are reproduction and care-giving, particularly when
those two align.56 Simultaneously, when compared with the
acceptability of paying women to provide their eggs for
51. Melinda Beck, Ova Time: Women Line Up To Donate Eggs – for
Money, WALL ST. J., Dec. 9, 2008, at D1.
52. Angel, supra note 14, at 214-15 (noting that “[o]ne written opinion in
the report by President Bush‟s Commission on Bioethics states that
„financially vulnerable populations‟ will be disproportionately represented
among oocyte donors for research”); Rao, supra note 48, at 1059-60.
53. Gerber, supra note 19, at 221.
54. Korobkin, supra note 2, at 46.
55. Angel, supra note 14, at 200.
56. Rao, supra note 48, at 1061-63.
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reproductive purposes, proponents also worry that a ban on
compensation to women supplying their eggs for research
purposes may elevate the importance of women serving as
reproduction vehicles: such a ban may signal that paying
women for their eggs for reproductive purposes is only fair
because women, first and foremost, are innately made for
reproduction and only that work deserves value.57 In short,
proponents contend that if payment is acceptable in the
reproduction context, it should be acceptable in the research
context because the procedures undergone by women providing
eggs for either purpose are the same.58
As to the assertion that only the removal of monetary
incentives will permit women to truly consent to supplying
their eggs, proponents of compensation note that this argument
extends too far. Though compensation may factor, perhaps
heavily, into a woman‟s decision to supply her eggs or may
cause a woman‟s husband to offer her up, the fraud in South
Korea demonstrates that payment is not the only catalyst for
forcing women to provide their eggs. Even when compensation
is disallowed, proponents observe that women may experience
intense pressure and find themselves in situations ripe for
exploitation.59
Therefore, proponents stress that it is more important to
provide women with adequate information about the egg
extraction procedure so that they can make informed choices
than to dissuade them from undergoing a risky procedure
based on a theory smacking of paternalistic protection that

57. Bercovici, supra note 2, at 209 (“Regulations on compensation thus
must apply equally to egg donation for IVF and research, sending a message
that female work is valued equally, whether it be for reproductive or research
purposes.”); Green, supra note 20, at 139 (“The view that women can be paid
for eggs for reproductive but not research purposes may reflect the belief that
maternally related sacrifices are somehow proper to women, whereas a
commitment to science research is not.”).
58. Rao, supra note 48, at 1065.
59. Bentley & Thacker, supra note 44. This study found that although
monetary payment may increase willingness to participate in medical
research, such payments do not “blind respondents to risk.” The study notes,
however, that what constitutes undue influence based on monetary
incentives differs from one individual to another: “It is not the dollar amount
alone that determines what is undue inducement; the impoverishment of
subjects and the risk of injury from the study are also considerations.” Id.
This insight is addressed in Part III.
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only when women are not distracted by money or other
inducements can they make a choice about that procedure.60
Permitting compensation and establishing a structure under
which women can truly decide whether to supply their eggs
after being presented with all the relevant information may
guard against the type of exploitation experienced in South
Korea: egg donation will transform from a mysterious
procedure, the full logistics mostly unknown by the relevant
population,61 deemed something that should be agreed to
through solely altruistic motivations, into a procedure openly
discussed and accompanied by general practices like other
medical research.62 Hence, according to proponents, the key to
protecting women is ensuring: (1) that they are fully informed
about the risks of egg extraction, including the uncertainty of
risk; (2) that potential conflicts of interests are minimized; (3)
that the circumstances of each woman contemplating donation
are considered to determine whether monetary or other
incentives are unduly inducing her to supply her eggs; (4) that
research regarding the risks is bolstered; and (5) that women
are assured medical treatment during and after the egg
extraction process.63

60. See Korobkin, supra note 2, at 52 (“[T]he suggestion that donors are
not able to make a voluntary decision when money is at issue takes on the
added connotation of gender stereotype and discrimination.”).
61. See supra note 43 and accompanying text (demonstrating that,
overall, women do not know the logistics of egg extraction). See also
Reichard, supra note 29 (reporting on a Romanian woman who agreed to sell
her eggs in order to raise money for her wedding, who then spent fourteen
days in intensive care because of complications with the extraction process,
but who refused to tell her doctors that she had undergone egg extraction
seemingly because she viewed admitting she had sold her eggs as shameful).
62. See Rao, supra note 48, at 1065-66 (noting that by “denying [women]
any right to receive compensation or otherwise share in the profits [of stem
cell research], . . . the rubric of privacy [is invoked]. . . . The problem is that
privacy . . . provides no power to control the body part . . . .”).
63. See, e.g., Bentley & Thacker, supra note 44 (commenting on the
variability of undue inducement); John A. Robertson, Assisting Reproduction,
Choosing Genes, and the Scope of Reproductive Freedom, 76 GEO. WASH. L.
REV. 1490, 1504 (2008) (proposing “greater attention to informed consent,
clinical practice, and coverage of medical care in the case of injury”); Spar,
supra note 3, at 1290 (discussing the need for research).
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B. Commodification
Second, opponents of compensation declare that permitting
payment will lead to the commodification of women and of
human life. In the context of egg donation for reproductive
purposes and surrogacy, some feminists argue that “in this
nonideal world of ours, treating women like anonymous
fungible
breeders
objectifies
them
and
recreates
Likewise,
opponents
claim
that
subordination.”64
compensating women for supplying their eggs for stem cell
research objectifies them by “translat[ing] women‟s bodies and
their physiological processes into a product,” thereby turning
women and their reproductive material into chattel,
diminishing the value of the individual generally, and violating
conceptions of personhood.65 Paying a woman for her eggs also
amounts to paying for a bodily intrusion, which similarly
undermines personhood.66 Further, opponents assert that
combining payment with donation for research purposes might
create a caste system: minority women, poorer women, and
women without academic or athletic achievements will become
the suppliers of eggs for research while white women,
economically-advantaged women, and accomplished women
(according to societal norms) will continue to provide eggs for
reproductive purposes.67
Proponents of compensation rebut that selling eggs,
especially for use in stem cell research, does not objectify
women nor does it violate conceptions of individuality and
personhood.68 Rather, proponents declare that restricting
women‟s choices through prohibiting payment serves to
infantilize women, constricting their autonomy, depriving them
64. MARGARET JANE RADIN, CONTESTED COMMODITIES: THE TROUBLE WITH
TRADE IN SEX, CHILDREN, BODY PARTS AND OTHER THINGS 149 (1996).
65. Angel, supra note 14, at 213-14.
66. Id. at 214; see also Lynn M. Squillace, Too Much Of A Good Thing:
Toward A Regulated Market In Human Eggs, 1 J. HEALTH & BIOMEDICAL L.
135, 143 (2005) (“Egg donation has also been viewed as the ultimate form of
patriarchy, where male doctors and egg brokers encourage healthy, fertile
female donors to undergo invasive procedures . . . at unknown risk to the
donor.”).
67. Angel, supra note 14, at 215.
68. See, e.g., RUSSELL KOROBKIN, STEM CELL CENTURY 193 (2007)
(“[S]elling a cycle of eggs does not, in itself, interfere with the ability of the
seller to fulfill an essential element of personhood . . . .”).
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of an aspect of reproductive control, denying them a source of
power and liberation, enforcing paternalism, and entrenching
inequality.69
Proponents of compensation emphasize that
women should be allowed to make their own decisions with
respect to the appropriate uses of their bodies, provided that
they are fully informed of the risks of those decisions.
Further, though receiving compensation for bodily
intrusion might undermine personhood, proponents note that
payment for providing eggs for reproductive purposes has
proceeded for many years without noticeably damaging the
dignity of women. Indeed, as viewed by proponents, the sale of
eggs for reproductive purposes seems more troubling than the
sale of eggs for research purposes: for reproduction, women
with certain attributes are preferred, which implies that
certain women are worth more than other women. Contrary to
fears about creating a caste system, permitting compensation
in both contexts may mitigate this implication: other than
genetic diversity, researchers do not prefer particular
Additionally, returning to discord between
attributes.70
permitting payment for supplying eggs in the reproductive
context and disallowing payment in the research context,
proponents of compensation assert that even if extracting eggs
from women may lead to their commodification and the
entrenchment of their subordination, payment alone will not
produce this outcome: this consequence is just as likely if
altruistic donation is permitted.71
Separate from arguments regarding the commodification of
women, opponents of compensation argue that embryos are
equivalent to persons, and, thus, selling embryos and their
component parts—including eggs—disrespects human life.72 In
response, proponents note that this argument is made with the
ultimate goal of preventing stem cell research based on views
about human life and has nothing to do with a concern for
women. Accordingly, proponents contend that this argument
relates to the debate about the propriety of stem cell research,
69. Angel, supra note 14, at 216 (“Many commentators find that the
entire argument against the commodification of oocyte donation . . . devalues
women as autonomous equals.”); Squillace, supra note 66, at 143.
70. KOROBKIN, supra note 68, at 194-95; Gruen, supra note 22, at 301-03.
71. KOROBKIN, supra note 68, at 195.
72. Bercovici, supra note 2, at 208.
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not the question of compensating women who provide their
eggs for such research once it is decided that the research
should proceed.73
C. Other Concerns
Though not raised by opponents or proponents of
compensation, as New York is the only state that permits
compensation for providing eggs for use in stem cell research,
concerns about creating a new form of “reproductive tourism”
are warranted. In the context of other reproductive technology,
instances of women traveling to jurisdictions that permit
Similarly, allowing
compensation are well-documented.74
compensation may attract women from other states and
countries to New York. Taking as given that women will
supply their eggs for both reproductive and research purposes,
I argue that the best solution is to recognize the potential
problem and enact safeguards to ensure that all women
contemplating supplying their eggs, including those traveling
from other jurisdictions, are able to make free and informed
choices.
Indeed, taking as given payment to women providing their
eggs for reproductive purposes and the acceptability of
altruistic donation for both reproductive and research
purposes, I find the arguments for permitting payment for
research purposes persuasive: not permitting compensation
may elevate the importance of women as reproductive vehicles
and entrench notions about women‟s natural altruism in the
areas of reproduction and care-giving. In an imperfect society
where women are exploited and subordinated such that
compensation becomes a concern as to their continued
73. Id. at 208-09; Rao, supra note 48, at 1065.
74. See, e.g., Beeson & Lippman, supra note 27, at 577 (relating the story
of “impoverished, semi-literate young Romanian factory workers . . .
repeatedly sell[ing] their eggs for US $250 to make up for the absence of
employment opportunities that provide a living wage”); June Carbone &
Paige Gottheim, Markets, Subsidies, Regulation, and Trust: Building Ethical
Understandings Into the Market for Fertility Services, 9 J. GENDER RACE &
JUST. 509 (2006) (discussing reproductive tourism); Lisa C. Ikemoto,
Reproductive Tourism: Equality Concerns in the Global Market for Fertility
Services, 27 LAW & INEQUALITY: J. THEORY & PRAC. 277 (2009) (also discussing
reproductive tourism).
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exploitation and the entrenchment of their subordination, the
Board‟s solution of paying women who supply their eggs to
stem cell research may be the better alternative: it is the
alternative which takes into account the reality that women
already are supplying their eggs in an atmosphere of
incomplete information and potential coercion,75 and which
posits that providing women with full information and the
ability to make their own decisions, including as to accepting
payment, will enhance their autonomy.
Nevertheless, perhaps the more pertinent question is
whether eggs should be harvested from women for any purpose
at this time: the process of egg extraction is so risky and
unstudied that subjecting women to it may be improper until
more research is completed. Historically, untested hormones,
including diethylstilbestrol and hormone replacement therapy,
have been used to abuse women‟s reproductive functions.76
Considering this and other historical subordination of women
by the sciences,77 a temporary prohibition against the
extraction of eggs from women who do not need to undergo the
procedure to have children themselves, such as for IVF, may be
warranted. Only after comprehensive research is conducted
and women can truly consider what undergoing egg extraction
may mean for them and women‟s status generally should the
question of the propriety of subjecting women to egg extraction
be re-apprised.
III. Bolstering the Board‟s Decision
Having decided to pay women who supply their eggs for
stem cell research, the Board appropriately recognized the
potential for the undue influence and exploitation of these
women.78 In recognizing this possibility, the Board outlined
safeguards that begin to incorporate some of the insights
75. See supra notes 49-51 and 61, and accompanying text.
76. Beeson & Lippman, supra note 27, at 575.
77. See, e.g., DONNA J. HARAWAY, SIMIANS, CYBORGS, AND WOMEN 8 (1991)
(“The degree to which the principle of domination is deeply embedded in our
natural sciences . . . must not be underestimated. . . . Women know very well
that knowledge from the natural sciences has been used in the interests of
our domination and not our liberation.”).
78. See supra note 8 and accompanying text.

19

2010]

PAYING WOMEN FOR THEIR EGGS

919

advanced by both opponents and proponents of compensation
as to what may lead to or evidence undue influence and
exploitation. Roughly, the Board has pledged: to pay women
who supply their eggs “reasonably” and an amount less than
“valuable consideration”; not to vary the amount of
compensation based on the outcome of the egg extraction
process, the characteristics of the woman supplying her eggs,
or that woman‟s prior history of producing eggs; to disclose all
of the risks, including psychological risks, associated with egg
extraction; to obtain informed consent by following a “dynamic
process” including counseling; to provide doctors‟ services to the
women supplying their eggs; and, finally, to implement
“rigorous review by an institutional oversight committee.”79
Though the Board‟s safeguards begin to address some
dangers of women‟s potential interactions with its
compensation program, overall, the above statements read
rather murky and malleable. What constitutes “valuable
consideration”? How will the “dynamic process” of informed
consent proceed? To what extent will doctors‟ services be
provided?
What constitutes “rigorous review” by the
institutional oversight committee? Also, all of the Board‟s
safeguards address concerns raised with regard to women
providing their eggs for reproductive purposes.80 The Board‟s
compensation program, however, may appeal to a diverse group
of women. Will (and how will) the institutional oversight
committee‟s “rigorous review” address the potential differences,
on average, between women who supply eggs for reproductive
purposes and women who supply eggs for research purposes?
Further, given the unknown long-term risks of egg production
and extraction, does (and how does) the Board intend to
address the potential continuing needs of the women it
encourages to undergo a risky medical procedure? The Board
can strengthen its decision by clarifying these and similar
questions.
Perhaps most critical to ensuring the well-being of the
entire universe of women who supply their eggs, the Board
79. Statement of Board, supra note 1.
80. See generally Ethics Comm., Am. Soc‟y for Reprod. Med., supra note
9 (outlining safeguards aimed at women providing their eggs for reproductive
purposes). Similarly, all of the Board‟s safeguards should apply equally to
women supplying their eggs for reproductive purposes.
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should clarify “valuable consideration” beyond paying a woman
less than $10,000 per egg extraction procedure.
What
constitutes valuable consideration such that the compensation
creates undue inducement will vary based on the
circumstances of the woman supplying her eggs.81 A college or
graduate student82 who intends to use the money to pay
student loans may conceptualize $10,000 much differently than
a woman who intends to use the money to feed her children or
pay for housing. Likewise, a woman who earns around
minimum wage, about $15,000 per year,83 and who anticipates
few future increases in income, will view $10,000 much
differently than a college-educated woman in her twenties or
early-thirties who foresees a lifetime of career advancement.
In the context of surrogacy, for which women are paid on
average about $10,000 and which similarly raises concerns
about class and race-based exploitation,84 some surrogacy
agencies and contracts prescribe that the woman
contemplating acting as a surrogate must make a minimum
income or be above a certain wealth line in order to become a
surrogate.85 The Board should implement a similar rule. This
rule will distinguish those women whose financial situations
create a substantial likelihood that being compensated
thousands and thousands of dollars to provide their eggs will
lead them to discount the risks of egg extraction so greatly that
they cannot be said to have made a real choice.86 Though not
all women falling below the minimum income or wealth line
81. See supra note 59 and accompanying text.
82. See, e.g., Angel, supra note 14, at 198 (discussing the characteristics
of women sought to provide eggs for reproductive purposes).
83. Effective July 24, 2009, the federal minimum wage is $7.25 per hour.
Fair Labor Standards Act, 29 U.S.C. § 206(a)(1)(C) (2006).
84. CATHARINE A. MACKINNON, SEX EQUALITY 1193-94, 1205 (2d ed.
2007).
85. See LORI ANDREWS, BETWEEN STRANGERS 64-65 (1989); Mark
Strasser, Parental Rights Terminations: On Surrogate Reasons and
Surrogacy Policies, 60 TENN. L. REV. 135, 215 (1992). Special thanks to
Professor Catharine MacKinnon for noting this parallel.
86. See Gruen, supra note 21, at 303 (positing that if $5,000-$15,000 was
“routinely offered to women of color in exchange for oocytes, it is much more
likely that significant problems with exploitation and undue influence would
surface”). These women also may withhold important medical information,
the disclosure of which would prohibit them from undergoing the egg
extraction procedure. See HUMAN FERTILISATION & EMBRYOLOGY AUTH., supra
note 4, at 13.
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will discount the risks of egg extraction so severely, such a rule
will serve as a proxy for the undue influence against which the
Board has pledged to protect. Moreover, given that the egg
extraction procedure is risky and understudied and that the
women providing their eggs to stem cell research are unlikely
to see a direct medical benefit—and thereby can be posited to
be providing their eggs solely for the advancement of science,
or, more likely, the money87—potentially precluding some
women who are not being unduly influenced from supplying
their eggs in exchange for preventing other women from
agreeing to egg extraction without making a real choice seems
a reasonable tradeoff, at least until the risks of egg extraction
are better understood.88
In addition, as to informed consent and the disclosure of
the risks associated with egg extraction, studies demonstrate
that how egg “donation” is presented to women upon first
contact impacts their ongoing perceptions of the risks of the egg
extraction procedure.89 Thus, it is important that when a
woman initially contacts an entity affiliated with New York‟s
compensation program, she be given an accurate description of
the egg extraction procedure and all the possible associated
risks prior to a discussion of compensation. Medically-trained
personnel should take the initial call so that any questions
about the procedure and the risks are answered immediately.
Following this call, the woman should receive a standardized
written information pamphlet, which will allow her to
contemplate its contents before she meets anyone in-person:
first hearing about the procedure and its risks in-person may
87. See supra notes 42 & 43, and accompanying text.
88. Such concerns are especially poignant given that egg production and
extraction necessarily involve an invasive medical procedure that shuts down
and then stimulates a woman‟s reproductive functions. See supra notes 2527, and accompanying text.
89. See, e.g., Carson Strong, How Should IVF Programs Handle Initial
Disclosure of Information to Prospective Ovum Donors?, 1 AM. J. OF BIOETHICS
23, 23-24 (2001) (discussing the results of a “study evaluating the
thoroughness with which infertility programs provide information about the
risks of ovum donation when first contacted by prospective donors”); Gregory
Stock, Eggs For Sale: How Much is Too Much?, 1 AM. J. OF BIOETHICS 26, 26
(2001) (noting that the same study “suggest[s] that many egg-donation
agencies offer limited, perhaps ever disingenuous risk information during
preliminary phone calls from prospective egg donors” and that this “might
influence some of these potential donors to behave differently had they gotten
more detailed risk information up front”).
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pressure the woman into agreeing to the procedure.90 This
pamphlet should summarize, clearly and honestly, the risks of
egg production and extraction, including the fact that the risks
are generally unknown and unstudied, using plain language,
such as stating that women can and have died from OHSS
rather than vaguely noting that OHSS can be “lifethreatening.” In connection with egg donation for reproductive
purposes, the New York State Department of Health provides a
guidebook for women contemplating egg donation entitled
Thinking of Becoming an Egg Donor?91 The Board can tailor
this pamphlet for stem cell research, perhaps changing the
wording so “supply” or “provide” eggs replace the inapt “donor”
and “donation.”
Once a woman meets in-person about supplying her eggs,
three counseling sessions should be required as part of the
“dynamic process” of informed consent: one with a doctor to
discuss the medical procedure and its risks; another with a
psychologist to discuss the potential psychological effects of egg
extraction, including the psychological effects of providing eggs
to stem cell research, for which the woman will receive no
direct benefit and for which the woman‟s eggs may be used in
unforeseeable ways;92 and a third with a patient advocate to
discuss the woman‟s decision-making process to supply her
eggs. This patient advocate should engage the woman in a
conversation about why and how she decided to supply her
eggs, discussing with the woman whether she appreciates all
the consequences of her decision and whether she is
discounting the risks of the procedure because of financial or
other concerns,93 thereby potentially eliciting information
about the woman being unduly influenced into providing her
eggs. For example, this conversation may uncover that the
woman‟s husband is demanding she supply her eggs and that

90. See Strong, supra note 89, at 24-25 (additionally noting that an inperson meeting involves a time commitment that may make a woman more
likely to agree to the procedure).
91. N.Y. STATE TASK FORCE ON LIFE & THE LAW, THINKING OF BECOMING
AN
EGG
DONOR?,
available
at
http://www.health.state.ny.us/publications/1127.pdf.
92. See Ikemoto, supra note 17, at 775.
93. See Ethics Comm., Am. Soc‟y for Reprod. Med., supra note 9, at 307
(suggesting similar).
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she would not do so but for the pressure.94 To further guard
against undue influence, if someone calls on a woman‟s behalf,
perhaps inquiring about how much she can make for providing
her eggs, information about that person and the nature of the
inquiry should be recorded and given to the patient advocate.
Together with the initial provision of the pamphlet, these three
sessions will provide a woman contemplating supplying her
eggs with comprehensive information and sufficient time to
consider that information, guarding against the making of a
rash decision based on incomplete information (potentially a
proxy of undue influence) to provide her eggs when confronted
with the possibility of earning thousands of dollars.
All of these interactions, from the initial phone call
through the in-person meetings and the egg extraction, should
occur with people and entities unaffiliated with the researchers
who will use the supplied eggs: researchers who need eggs to
conduct their research unintentionally might downplay the
risks of egg extraction.95 Likewise, to prevent situations akin
to the scandal in South Korea, situations in which a woman
may feel pressured (and thereby may be exploited) by a familial
or employment relationship into providing her eggs, a woman
who has a relationship with the researchers who will use her
eggs or the doctors who will extract her eggs should be
prohibited from undergoing egg extraction.96 To insulate the
patient advocates‟ interaction with women, thereby allowing
women to talk freely with them, the patient advocates should
be unaffiliated with the doctors and counselors attending the
women.
Additionally, the Board should allocate a portion of its
funds to conducting research about the demographic and
94. See supra note 51 and accompanying text. In this regard, a patient
advocate may uncover domestic violence, especially considering that domestic
violence increases in times of financial strain and that financial strain may
cause a husband to demand that his wife supply her eggs in order to relieve
that strain. See, e.g., Peter C. Alexander, “Herstory” Repeats: The Bankruptcy
Code Harms Women and Children, 13 AM. BANKR. INST. L. REV. 571, 579-80
(noting the link between financial difficulties and domestic violence).
Accordingly, patient advocates should have adequate knowledge to direct
women to domestic violence support services.
95. See Ikemoto, supra note 17, at 775 (discussing standards created by
the California Institute for Regenerative Medicine, which impose similar
requirements).
96. See Gruen, supra note 21, at 304 (suggesting similar safeguards).
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socioeconomic composition of the women it compensates to
provide their eggs.
Such research will generate needed
information about the backgrounds of women who supply their
eggs for stem cell research. This information can be used,
perhaps by the “institutional oversight committee,” to tailor the
“dynamic process” of informed consent to the needs and
educational level of the women interacting with it, thereby
ensuring that the women contemplating supplying their eggs
make fully informed decisions.97
Further, if at any time during egg production the woman
wants to stop the procedure, she should be allowed to do so
without repercussions: she should be paid proportionally for
the part of the procedure she fulfilled, and she should be
offered all the continuing medical and other care women who
complete egg extraction are given. Considering the potential
for long-term risks arising from egg extraction, after the
extraction, the woman should be offered continuing no-cost
medical care for both physical and psychological needs caused
by undergoing the procedure, including suggested follow-ups to
assess her ongoing condition and to gather data for research
about the effects of egg production and extraction.98
Individuals and entities affiliated with this care should be
unassociated with the researchers who intend to use the
supplied eggs and with the doctors who extracted the eggs,
both groups of whom may have a stake in ensuring that women
do not report severe (or any) problems with egg production and
extraction.
To reduce the potential health risks of egg extraction, the
number of times a woman may undergo egg extraction should
be limited to at most six, and women at higher risk for
developing OHSS should be prohibited from providing their
eggs or should be allowed only to supply their eggs if they do
not undergo ovarian hyper-stimulation.99 Indeed, in light of
97. If the Board is concerned about creating a caste system under which
certain women provide eggs for stem cell research while certain other women
provide eggs for reproductive purposes, the Board can use this information to
ensure that those women, on average, who provide eggs for reproductive
purposes are also supplying their eggs for stem cell research.
98. See Ikemoto, supra note 17, at 775 (discussing standards created by
the California Institute for Regenerative Medicine, which stipulate that nocost continuing medical care must be provided).
99. See ADAM BALEN, OVARIAN HYPERSTIMULATION SYNDROME (OHSS): A
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the dearth of research about the short and long-term effects of
ovarian hyper-stimulation, if the Board is serious about
protecting the women it entices to provide their eggs, the Board
should implement a rule that no eggs may be harvested from
women using ovarian hyper-stimulation.
Such a rule
necessarily will decrease the number of eggs extracted from
each woman, but also will decrease the compensation amount
reasonably due to each woman and may increase the number of
women willing to provide their eggs. These effects considered
together, the Board may be able to purchase a similar amount
of eggs for a similar amount of money while drastically
decreasing the potential risk to women by mandating that
women be “naturally cycled” when they provide their eggs.
Overall, though some of these safeguards may seem excessively
burdensome and restrictive, considering the many risks of—
and dearth of research concerning—the egg extraction
procedure, the lack of direct benefit beyond payment to women
supplying their eggs, and that these women do not need to
undergo egg extraction but to advance stem cell research, these
safeguards should be viewed as appropriate and sound, at least
until more is known about the risks of egg extraction.
Finally, returning to the need for research, the Board
should allocate a portion of its funds to conducting studies of
the short and long-term effects (both physical and
psychological) of egg production and extraction.100 If the Board
is prepared to advertise its compensation program to tens
(perhaps hundreds) of thousands of women and to extract
hundreds upon hundreds of eggs from them, as will be needed
for stem cell research, then the Board should be willing to
spend money to determine how the procedure is affecting the
women it is paying.

SHORT REPORT FOR THE HFEA 14 (2008) (Eng.), available at
www.hfea.gov.uk/docs/OHSS_UPDATED_Report_from_Adam_Balen_2008.pd
f (detailing the risk factors for OHSS, suggesting to “limit[ ] the number of
stimulated cycles for a given oocyte donor to approximately six,” and
generally discussing the risks of OHSS). See also supra note 32.
100. See Spar, supra note 3, at 1290 (detailing what these studies should
entail).

https://digitalcommons.pace.edu/plr/vol30/iss3/4
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IV. Conclusion
Taking the payment of women who provide eggs for
reproductive purposes and the allowance of altruistic donation
for research as given, the Board, acting on behalf of the State of
New York, has decided to compensate women for providing
their eggs for stem cell research. As the first state to allow
payment to women in this context, it is critical that the Board
adequately and effectively monitor the consequences of its
program. In addition to clarifying the safeguards it has
outlined in its written opinion, the Board should bolster its
decision by adding requirements that take into account the
possible differences between women who provide their eggs for
reproductive purposes and women who provide their eggs for
stem cell research, and that address the potential continuing
needs of all women who provide their eggs. Particularly,
adding income or wealth requirements, and allocating a portion
of its funds to conducting research about the demographic and
socioeconomic composition of the women it compensates, and
physiological and psychological effects of the egg extraction
procedure on those women, will facilitate what should be New
York‟s primary goals as to how women interact with its
payment program: to identify and reduce the percentage of
women unduly induced or exploited into providing their eggs,
thereby allowing women to exercise the fullest possible control
over their bodies, and to ensure that those women who do
freely provide their eggs are able to do so with the greatest
possible knowledge of the risks of egg production and
extraction.
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